All conditions

Cardiomyopathy

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

1507
Trials on record
301
Recruiting now
6
Australian sites
20
Phase 3 trials
2
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Cardiomyopathy →

Get alerts when Cardiomyopathy trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle itself. In people with this condition, the heart muscle becomes enlarged, thickened, or stiffened in a way that makes it harder for the heart to pump blood around the body effectively. Unlike some other heart conditions, cardiomyopathy is not caused by blocked arteries or high blood pressure — it originates within the muscle tissue itself. There are several different types, and the way the condition develops and progresses can vary quite a bit from person to person.

Cardiomyopathy affects Australians of all ages, including children and young adults, though it becomes more common as people get older. It is estimated to affect tens of thousands of Australians, and in some cases it runs in families, meaning a genetic change can be passed down through generations. Because of this, close relatives of someone diagnosed are sometimes recommended to have their own heart checked.

When it comes to managing cardiomyopathy, doctors generally focus on reducing symptoms, slowing the progression of the condition, and lowering the risk of complications such as heart failure or irregular heart rhythms. Treatment approaches can include medications, lifestyle changes, and in some cases procedures or devices to support the heart's function. The right approach depends on the type of cardiomyopathy, how severe it is, and the individual's overall health. A cardiologist — a heart specialist — will typically be closely involved in ongoing care, and it is worth asking them any questions you have about your specific situation.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Cardiomyopathy in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Cardiomyopathy

2 medicines listed on the PBS for Cardiomyopathy. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 2 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
mavacamten Camzyos Symptomatic obstructive hypertrophic cardiomyopathy AU$2160.7 Authority required
Tafamidis Vyndamax Transthyretin amyloid cardiomyopathy AU$9860 Authority required

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Cardiomyopathy currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Cardiomyopathy.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Cardiomyopathy by country. Australia is highlighted.

Showing the top 10 of 61 countries with trial sites.

Clinical trials for Cardiomyopathy

Showing 302 of 302 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00358215 · Amgen Phase 3 · 36 countries Completed
Completed Phase 3 Est. completion 11 October 2012
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇱 CL +28 more

**Who might be able to join this trial:** - You have been living with heart failure for at least 3 months, and your symptoms are classified as moderate to severe (NYHA class II, III, or IV — confirm with trial site if unsure of your class) - Your red blood cell levels (hemoglobin) are mildly low, falling between 9.0 an...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05164328 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 23 June 2035
🇦🇺 AU🇧🇪 BE

Who might be able to join this trial: - People aged 14 to 23 years old, either male or female - Athletes who have competed in endurance sports at a national or international level for at least 2 years, in sports such as triathlon, cycling, distance running (races of 1500 metres or longer), rowing, or swimming - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06128629 · Intellia Therapeutics Phase 3 · 26 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇿 CZ🇩🇰 DK +18 more

**Who might be able to join this trial:** - People who have been formally diagnosed with ATTR amyloidosis that has affected the heart (a condition where abnormal proteins build up in the heart muscle) - People who have a medical history of heart failure - People whose heart failure symptoms are well-controlled and who...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06360939 · Western Sydney Local Health District Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 June 2026
🇦🇺 AU

**Who might be able to join this trial:** - People who have a structural heart condition — such as a heart affected by blocked arteries, a weakened heart muscle, or a heart defect present from birth — where heart scans or tests show abnormal heart wall movement, thickened heart muscle, or scarring in the heart. - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06563895 · Eidos Therapeutics, a BridgeBio company Phase 3 · 24 countries Recruiting
Recruiting Phase 3 Est. completion 1 October 2031
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE +16 more

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) - You have had a genetic test (for medical reasons) that confirmed you carry a gene change in the TTR gene that is known or likely to cause disease (for example, variants called V30M, V122I, T60A, or others) - Your age is within...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07052903 · Alnylam Pharmaceuticals Phase 3 · 35 countries Recruiting
Recruiting Phase 3 Est. completion 28 May 2030
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN +27 more

Who might be able to join this trial: - People who have a confirmed diagnosis of ATTR amyloidosis affecting the heart, either the inherited form (hATTR) or the age-related form (wATTR). - People who have a history of heart failure, with at least one previous hospital stay for heart failure, or who have heart failure sy...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07207811 · Novo Nordisk A/S Phase 3 · 20 countries Recruiting
Recruiting Phase 3 Est. completion 29 June 2029
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇩🇰 DK +12 more

**Who might be able to join this trial:** - You are 18 years of age or older - You have been formally diagnosed with a condition called ATTR cardiomyopathy (a disease where a protein called TTR builds up in the heart), either the inherited type or the age-related type - Your diagnosis has been confirmed through a hear...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00733590 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇺🇸 US

Who might be able to join this trial: - People who have had a heart attack at least 4 weeks ago - People who have had reduced heart pumping function (not caused by blocked arteries) for at least 9 months - People whose heart is pumping at 35% or less of its normal capacity - People who have had their ICD (implanted hea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01076660 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - People whose heart is pumping at 35% or less of its normal capacity, and who have been referred by their doctor to have a defibrillator device (ICD) implanted to prevent a serious heart rhythm problem from happening in the future (not because one has already occurred) - People be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01091480 · French Cardiology Society Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2023
🇫🇷 FR

Who might be able to join this trial: - You are 15 years old or older - You have been diagnosed with hypertrophic cardiomyopathy (HCM), which means the wall of your heart's main pumping chamber is thickened — at least 13mm thick if other family members have the condition, or at least 15mm thick if no family members are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01999140 · American College of Cardiology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇺🇸 US

Who might be able to join this trial: - People who receive an ICD (implantable cardioverter-defibrillator) or CRT-D (a combined heart rhythm and resynchronisation device) for the first time or as a replacement device, for either preventative reasons or because they have already had a serious heart rhythm problem. - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02445534 · University Medical Centre Ljubljana Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇸🇮 SI

Who might be able to join this trial: - Adults between 18 and 65 years old - People who have been diagnosed with dilated cardiomyopathy (a condition where the heart is enlarged and cannot pump blood properly) according to established European cardiology guidelines - People who have been on the best available standard m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02641145 · Brigham and Women's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are older than 18 years of age - You have been diagnosed with light chain (AL) amyloidosis confirmed through standard blood, urine, or tissue tests - If you are traveling from out of town and your biopsy results are still pending, you may be able to start the study befor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02696135 · China National Center for Cardiovascular Diseases Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a heart condition called hypertrophic cardiomyopathy (HCM), meaning your heart wall is thicker than normal (at least 15mm) as seen on a heart scan (echocardiogram or MRI), with no other known cause for the thickening. - If a close family member ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02804269 · National Heart Centre Singapore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2033
🇸🇬 SG

"Who might be able to join this trial: - People aged 16 to 90 years old. Who may not be able to join: - No specific exclusion criteria have been listed for this trial beyond the age requirement above. Important: Always verify eligibility with the trial site directly before applying."

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02855554 · Medical University of South Carolina Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - You must be between 18 and 90 years old. - You must have already been diagnosed with, or are suspected to have, one of these heart conditions: reduced blood flow to the heart or a heart attack, a thickened heart muscle (hypertrophic cardiomyopathy), a heart muscle affected by a b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02962661 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You have a weakened heart (reduced pumping ability of 40% or less) that was caused by chemotherapy drugs called anthracyclines, used to treat any type of cancer, at any dose and at any point in the past, with no other known cause for the heart weakness. - You are between 18...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03049254 · Mayo Clinic Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You survived a sudden cardiac arrest (heart suddenly stopping) that was NOT caused by a heart attack - A family member died suddenly from cardiac arrest that was NOT caused by a heart attack, and you are involved in their case - You had a sudden cardiac arrest that happened along...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03132129 · University of Leicester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2029
🇬🇧 GB

**Who might be able to join this trial:** - You are willing and able to give your consent to take part in the study - You are aged between 18 and 75 years old (inclusive) - You have been diagnosed with stable type 2 diabetes, confirmed by your GP's records along with either a glucose tolerance test or a specific blood...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03299569 · University of Aberdeen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with Takotsubo cardiomyopathy (a temporary heart condition, sometimes called "broken heart syndrome," where the heart muscle suddenly weakens) **Who may not be able to join:** - No specific exclusion criteria have been listed for this trial (co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03475498 · Eulji University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2027
🇰🇷 KR

**Who might be able to join this trial:** - People who are willing to take part in the study and are able to sign a consent form agreeing to participate - People who have had heart tests (an ECG, which records the heart's electrical activity, and an echocardiogram, which uses sound waves to create images of the heart)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03479580 · University Hospital, Grenoble Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with ischemic cardiomyopathy (heart muscle damage caused by reduced blood flow to the heart) - People who have been diagnosed with dilated cardiomyopathy (a condition where the heart becomes enlarged and cannot pump blood effectively) - People who h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03581318 · National Heart, Lung, and Blood Institute (NHLBI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
🇺🇸 US

**Who might be able to join this trial:** **As a healthy volunteer:** - People aged 7 years or older who do not have a known heart or cardiovascular condition - People who are able to follow instructions and lie still inside an MRI scanner - People who are able to give written consent, or whose parent or guardian is a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03586518 · University of Leicester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇬🇧 GB

**Who might be able to join this trial:** - You have been receiving kidney dialysis (haemodialysis) for more than 3 months - You are on a supportive (palliative) care programme and doctors expect that you may pass away within the next 12 months - You are able to give your informed agreement to take part in the study -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03593317 · Hospices Civils de Lyon Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who are older than 18 years of age - People who have been diagnosed with a heart condition called ARVD (a disease affecting the right side of the heart), confirmed using specific international diagnostic guidelines that require a combination of major and minor diagnost...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03663348 · NYU Langone Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with Takotsubo syndrome (a type of temporary heart condition, sometimes called "broken heart syndrome") by a doctor - People who are over 18 years of age Who may not be able to join: - People who are unable to understand and agree to participation...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03821051 · China National Center for Cardiovascular Diseases Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 October 2022
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with an irregular heartbeat (ventricular arrhythmia) that is caused by a structural problem with your heart, such as ischemic cardiomyopathy (heart damage from reduced blood flow), arrhythmogenic right ventricular cardiomyopathy (a condition where heart mu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03846297 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with a heart condition called hypertrophic cardiomyopathy (HCM), which means part of your heart wall is thicker than normal (confirm with trial site for exact measurements) - You are 16 years old or older - You either do not have an internal heart defi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03910569 · Cedars-Sinai Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2029
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Takotsubo (a type of heart condition, sometimes called "broken heart syndrome") by your doctor and agree to take part in the trial. - You are able to provide your full medical records needed for the trial team to confirm your diagnosis. Who may not b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04080492 · The Cleveland Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People aged 18 to 70 years old who have been diagnosed with hypertrophic cardiomyopathy (HCM), thoracic aortic disease (TAD), and/or radiation-induced heart disease (RIHD), and who are attending the Cleveland Clinic Main Campus for a full cardiac assessment to plan their care (co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04178434 · Per Tornvall Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2024
🇸🇪 SE

**Who might be able to join this trial:** - You have been told you may have had a heart attack with no blocked arteries (sometimes called MINOCA) or a condition called takotsubo syndrome (also known as "broken heart syndrome"), confirmed by a heart artery scan showing no major blockages - You are between 35 and 80 year...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04257994 · St. George's Hospital, London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2024
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with a hereditary heart rhythm or heart muscle condition — such as arrhythmogenic, hypertrophic, or dilated cardiomyopathy, cardiac sarcoidosis, Long QT syndrome, Brugada syndrome, or catecholaminergic polymorphic ventricular tachycardia (CPVT)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04265040 · University Hospital Heidelberg Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇩🇪 DE

**Who might be able to join this trial:** - People aged 18 to 80 years old - People who are able to understand and sign a consent form - People diagnosed with a non-ischemic structural heart muscle disease (a heart muscle condition not caused by blocked arteries), specifically at least one of the following: - People wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04281823 · Dipan Shah Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2058
🇺🇸 US

Who might be able to join this trial: - People who come to the Houston Methodist CMR Laboratory who have been diagnosed with, or are suspected to have, a heart or blood vessel condition. Who may not be able to join: - People who are unable to give their own consent to take part in the study (for example, if they are u...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04361994 · Prof. Dr. med. Ingo Eitel Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2035
🇩🇪 DE🇮🇹 IT

"Who might be able to join this trial: - You have been diagnosed with Takotsubo syndrome (a type of heart condition sometimes called "broken heart syndrome," where the heart muscle suddenly weakens, often triggered by stress) Who may not be able to join: - The exclusion criteria listed are unclear or incomplete (confi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04416958 · Klinikum-Fuerth Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇩🇪 DE

Who might be able to join this trial: - You are scheduled to receive a pacemaker or implantable defibrillator (ICD) device, with the goal of avoiding a specific type of irregular heart rhythm caused by the device itself, in line with current medical guidelines - You are 18 years old or older Who may not be able to joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04464655 · McGill University Health Centre/Research Institute of the McGill Unive... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2024
🇨🇦 CA

**Who might be able to join this trial:** *For healthy volunteers:* - You are over 18 years old and able to give informed consent - You do not have any known significant medical conditions that affect your heart or breathing *For patients:* - You are over 18 years old and able to give informed consent - You have alre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04476901 · Joshua M Hare Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 80 years old (inclusive) at the time of signing the consent form - People who have been diagnosed with non-ischemic dilated cardiomyopathy (a type of weakened, enlarged heart not caused by blocked arteries) with a heart pumping function of 45% or less -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04500665 · Brigham and Women's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 21 and 80 years old (inclusive) - Your kidneys are working at a reduced but not completely failed level, based on a specific kidney function test result (eGFR between 15 and 75) - A urine test shows a certain level of protein leaking into your urine (albumin-...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04504188 · Zoll Medical Corporation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2024
🇺🇸 US

**Who might be able to join this trial:** - You are a woman who has recently been diagnosed with a weakened heart (either caused by blocked arteries or another reason), and your heart's pumping ability is at or below 35% at the time you are given a wearable heart device (WCD). - You have been prescribed the wearable h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04513054 · University of Aberdeen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇬🇧 GB

Who might be able to join this trial: - People who have been diagnosed with Takotsubo cardiomyopathy (a type of heart condition sometimes called "broken heart syndrome") in Scotland at any point from 2010 to the present. - People anywhere in the world who have a family member also diagnosed with Takotsubo cardiomyopath...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04521790 · Scientific Institute San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇮🇹 IT

Who might be able to join this trial: - People who have given their written agreement to take part in the trial. - People who are 18 years of age or older. - People who have been clinically suspected of having myocarditis (inflammation of the heart muscle). - People who are enrolled through one of the medical centres o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04558723 · Prof. Dr. med. Ingo Eitel Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇩🇪 DE

**Who might be able to join this trial:** - People diagnosed with non-ischemic dilated cardiomyopathy (a type of heart muscle disease not caused by blocked arteries, either with no known cause or running in the family) - People whose heart pumping function is at or below 35%, and whose heart scan shows scarring in the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04591639 · University of Edinburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 July 2028
🇬🇧 GB

Who might be able to join this trial: **People with heart failure (with or without type 2 diabetes):** - Adults aged 18 or over - People who have had a diagnosis of heart failure with symptoms and reduced pumping function for at least 2 months - People whose heart's pumping capacity (ejection fraction) is 40% or less...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04612296 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇬🇧 GB

Who might be able to join this trial: - You must be 18 years of age or older - Both men and women are welcome to apply - You must be able to understand and agree to take part in the study yourself - You have been diagnosed with a heart muscle condition called cardiomyopathy or an inflammation of the heart called myocar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04634487 · Medical University of Warsaw Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2021
🇵🇱 PL

Who might be able to join this trial: - People who have been diagnosed with Takotsubo syndrome (a temporary heart condition, sometimes called "broken heart syndrome," where the heart muscle suddenly weakens) Who may not be able to join: - No specific exclusion criteria have been listed for this trial (confirm with tri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04641416 · Thomas Schlöglhofer, PhD, MSc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2026
🇦🇹 AT

**Who might be able to join this trial:** - People who have had a HeartMate 3 heart pump device implanted at the Medical University of Vienna - People who are able to understand and sign a consent form agreeing to take part in the study **Who may not be able to join:** - People who are under 18 or over 75 years of age...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04666454 · Vastra Gotaland Region Phase 4 · 3 countries Recruiting
Recruiting Phase 4 Est. completion 1 December 2028
🇩🇰 DK🇳🇴 NO🇸🇪 SE

**Who might be able to join this trial:** - People aged 18 years or older - People who have been clinically diagnosed with Takotsubo Syndrome (TS), including having a heart pumping function (ejection fraction) below 50% at the start of the trial - People who are able and willing to provide written consent to participat...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04813159 · University of Cape Town Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
Kenya Mozambique Senegal🇿🇦 ZA Sudan Uganda

**Who might be able to join this trial:** *For the main (randomised) part of the trial — patients arriving within 24 hours:* - You are 18 years old or older and are suspected to have had a serious type of heart attack (called a STEMI), shown by specific changes on a heart tracing (ECG). - Your heart attack symptoms be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04843371 · Tulane University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - You are 18 years old or older. - You are already scheduled to have a heart ultrasound (echocardiogram) at Tulane Medical Center. Who may not be able to join: - You are under 18 years of age. - You have a condition that affects thinking, memory, or understanding (cognitive impair...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04844151 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2041
🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with acute myocarditis (inflammation of the heart muscle), confirmed either by a special heart scan called a cardiac MRI or by a small tissue sample taken from the heart - You are enrolled in the French national health insurance system ("Sécurité sociale")...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04856059 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2029
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with Fabry disease - People who are 18 years of age or older Who may not be able to join: - People who have previously had a heart attack - People for whom MRI scans are not safe or suitable (for example, those with certain metal implants or pacema...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04924998 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2031
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 90 years old (any gender) and have been diagnosed with AL cardiac amyloidosis (a condition where abnormal proteins build up in the heart) at the Second Affiliated Hospital of Zhejiang University School of Medicine. - You are able to understand what the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04935021 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 June 2031
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 90 years old who have been diagnosed with ATTR-CM (a heart condition caused by a protein called transthyretin building up in the heart), or who carry the gene associated with this condition, confirmed at the Second Affiliated Hospital of Zhejiang University Scho...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04976348 · Maastricht University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2051
🇳🇱 NL

**Who might be able to join this trial:** - People who have been referred to a cardiology or genetics department because of symptoms that resemble heart failure, or for heart or genetic screening related to the heart. - People who are 16 years of age or older. **Who may not be able to join:** - People who do not wish...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04990297 · Chinese Academy of Medical Sciences, Fuwai Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇳 CN

**Who might be able to join this trial:** - People whose heart is not pumping blood as strongly as normal (the heart's pumping function is measured at less than 50%) - People whose heart's main pumping chamber is larger than the normal range for their body size and age **Who may not be able to join:** - People with an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05034432 · University of Rochester Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You are over 18 years old - You have been diagnosed with advanced heart muscle disease (of any severity level) and your heart failure medical team has decided you are a suitable candidate for a left ventricular assist device (LVAD), which is a mechanical pump to help your he...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05046002 · Ottawa Heart Institute Research Corporation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - People who were eligible to receive a COVID-19 vaccine. - People who experienced at least one heart-related symptom within 42 days of a COVID-19 vaccine, such as chest pain, chest pressure or discomfort, shortness of breath or pain when breathing, a pounding or irregular hea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05081115 · Fatebenefratelli Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2022
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with, or are suspected to have, coronary artery disease (a condition where the arteries supplying the heart become narrowed or blocked) - People who have hypertrophic cardiomyopathy (a condition where the heart muscle becomes abnormally thick) -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05098665 · Richmond Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇬🇧 GB

Who might be able to join this trial: - Adults aged 18 or older at the time of signing the consent form to take part in the study - People who have been diagnosed with ATTR cardiomyopathy (a heart condition caused by a protein called amyloid building up in the heart), as defined by the trial's criteria - People who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05112237 · Tenaya Therapeutics Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇨🇦 CA🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** *Retrospective part (using existing records):* - Children under 18 years old at the time they were enrolled or at the time of death, for whom medical data is available. - People who have genetic test results showing at least one harmful or likely harmful change (mutation) in a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05150704 · Niguarda Hospital Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 1 March 2028
🇦🇹 AT🇧🇪 BE🇨🇿 CZ🇫🇮 FI🇮🇹 IT🇸🇮 SI🇪🇸 ES🇸🇪 SE +1 more

**Who might be able to join this trial:** - You have been admitted to hospital with a suspected condition called myocarditis (inflammation of the heart muscle) - You are between 18 and 69 years old - You have signs of acute heart failure, confirmed by a blood test showing certain heart stress markers above a specific...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05180773 · Dennis M. McNamara, MD, MS Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 June 2026
🇺🇸 US

Who might be able to join this trial: - People who have recently been diagnosed with peripartum cardiomyopathy (a type of heart condition that develops around the time of childbirth) for the first time - People who have already given birth and are within the first 5 months after delivery - People whose heart pumping st...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05209776 · University Hospital, Toulouse Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇫🇷 FR

Here is the eligibility information in plain English: **Who might be able to join this trial:** - (For the main study group) People who have been diagnosed with a specific heart condition called arrhythmogenic right ventricular dysplasia (a disease affecting the right side of the heart's pumping chambers) and are sch...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05212792 · University of British Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - You received a COVID-19 vaccine and afterwards developed one of these conditions: Guillain-Barré Syndrome (a nerve disorder), a serious blood clotting and low platelet condition (sometimes called VITT or TTS), or inflammation of the heart or its surrounding lining (myocarditi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05214365 · Hospital Clinic of Barcelona Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇪🇸 ES

Who might be able to join this trial: - You must be 18 years of age or older. - You must be willing to take part and able to sign a consent form agreeing to join the study. - You must have a heart that is pumping well enough (with a specific heart function measurement above 50%) and have been recommended by your doctor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05321875 · Cristina Avendaño Solá Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 2 June 2026
🇪🇸 ES

**Who might be able to join this trial:** - People aged 18 to 64 years (any sex) who carry a gene variant known or likely to cause dilated cardiomyopathy (a condition where the heart muscle weakens and enlarges), as confirmed using recognised genetic classification guidelines. - People whose heart pumping function is a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05329285 · Vastra Gotaland Region Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇸🇪 SE

**Who might be able to join this trial:** - You are 18 years of age or older - You have been experiencing heart failure symptoms (such as shortness of breath or fatigue) rated as moderate to severe within the last month - Tests such as an ultrasound, MRI, or nuclear scan have shown that your heart's pumping strength i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05332691 · Xiang Wei Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have a significant blockage of blood flow leaving the heart (either at rest or when triggered), along with a notably thickened heart wall, as measured by specific medical tests. - People whose heart function has been rated as moderately reduced or worse according t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05335928 · Massachusetts General Hospital Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 20 November 2026
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who have given their written consent to participate before any study procedures begin (or whose legal representative has done so on their behalf, where permitted). - People aged 18 or older at the time of giving consent. - People who have recently received an FDA-appr...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05427370 · Sunnybrook Health Sciences Centre Not Applicable · 15 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2029
🇦🇹 AT🇧🇷 BR🇨🇦 CA🇨🇳 CN🇭🇷 HR🇪🇬 EG🇩🇪 DE🇮🇳 IN +7 more

**Who might be able to join this trial:** - You are over 18 years old - Your heart's pumping function is measured at 40% or less (called an "ejection fraction"), confirmed by a heart scan within the past 2 months - You have significant blockages in multiple heart arteries — specifically in three vessels, or in two ves...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05450783 · Nantes University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are male or female and are over 16 years old **Who may not be able to join:** - You or a close family member have a specific type of heart muscle disease affecting the left or both sides of the heart (called arrhythmogenic cardiomyopathy), AND carry a faulty gene variant...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05489549 · University of Texas Southwestern Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: **Group 1 – Carriers of a changed TTR gene (or matched non-carriers) without heart failure:** - Men and women aged 30–80 who carry a disease-causing change in the TTR gene (or who are matched non-carriers), and who have no history of heart failure, meaning: no hospital stay for he...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05489705 · Bristol-Myers Squibb Not Applicable · 7 countries Recruiting
Recruiting Not Applicable Est. completion 17 August 2029
🇦🇹 AT🇫🇷 FR🇩🇪 DE Puerto Rico🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older at the time you agree to take part. - You must be willing and able to sign a consent form before the study begins (or have a legal representative do so on your behalf if you are unable to). **If applying for the US part of the study:** -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05491655 · Miulli General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇮🇹 IT

Who might be able to join this trial: - People aged 18 or older - People whose heart is pumping at less than 50% of its normal capacity (as measured by a heart function test called ejection fraction) - People whose ejection fraction is between 36–50% and who also have elevated levels of certain heart stress markers in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05507879 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People with breast cancer who are starting treatment with doxorubicin or another similar chemotherapy drug (called an anthracycline), or who are receiving a drug called trastuzumab without that type of chemotherapy, as part of treatm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05511246 · The Methodist Hospital Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 12 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are a man or woman between 18 and 85 years old who already has an implanted defibrillator (ICD) device in your chest - You have been diagnosed with heart damage caused by a previous heart attack, confirmed by heart tests or imaging - You have had one of the following in t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05519046 · InCor Heart Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇧🇷 BR

**Who might be able to join this trial:** - People who are willing and able to sign a consent form before any study procedures begin - People aged between 18 and 75 years old (any gender) - People who have had a confirmed positive test for Chagas disease within the last two years, shown by at least two different blood...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05519735 · Wuerzburg University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇩🇪 DE

Who might be able to join this trial: - You have had a specific type of heart attack (called STEMI) and were treated quickly with a procedure to open the blocked artery (catheterization) - Your condition has been stable after the procedure - You are male or female and are 18 years of age or older Who may not be able t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05521451 · Universitätsklinikum Hamburg-Eppendorf Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇩🇪 DE

Who might be able to join this trial: - People who have a heart rhythm disorder (including one present from birth) that has already been diagnosed, or who have been identified as being at high risk of developing a heart rhythm disorder - People who are 18 years of age or older - People who are willing and able to give...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05556369 · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with a structural cardiomyopathy (a condition where the heart muscle is abnormally structured or weakened) - First-degree relatives (such as parents, siblings, or children) of someone diagnosed with cardiomyopathy Who may not be able to join: - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05568069 · University Hospital Southampton NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2029
🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with a specific type of heart condition called non-ischemic cardiomyopathy (a weakened heart not caused by blocked arteries), confirmed by a special type of heart scan using a dye (contrast-enhanced MRI). - Your heart MRI shows areas of scarring in th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05569382 · Morten Steen Kvistholm Jensen Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 April 2027
🇩🇰 DK

**Who might be able to join this trial:** - Adults aged 18 or older - People whose heart wall has a maximum thickness of 15mm or more, where this thickening is not caused by high blood pressure, valve disease, or a storage disease, AND who also meet at least one of the following conditions: - Their heart failure symp...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05610215 · China National Center for Cardiovascular Diseases Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with hypertrophic cardiomyopathy (a condition where the heart muscle is thickened), confirmed by an imaging test such as an echocardiogram, MRI, or CT scan, meeting specific thickness measurements based on genetic test...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05632432 · Hospital District of Helsinki and Uusimaa Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2026
🇫🇮 FI

**Who might be able to join this trial:** - You have agreed to take part and given your written consent - A heart scan (echocardiogram) has shown that your heart's pumping strength is between 15% and 40% (lower than normal) - You have been diagnosed with heart failure with symptoms ranging from mild (noticeable during...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05650658 · Baylor College of Medicine Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 30 June 2029
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People whose heart's pumping strength (measured as the left ventricle ejection fraction, or LVEF) has been recorded at 50% or below within the past 6 months - People who have had an electrical heart tracing (ECG) showing a delayed or widened electri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05651919 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 May 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are attending a scheduled cardiology or diabetes/hormone specialist follow-up appointment - You are willing to fast before having a blood sample taken - You are between 40 and 85 years old (inclusive) - You do not object to taking part in this research - You agree to hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05654272 · The Cleveland Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 September 2032
🇺🇸 US

Who might be able to join this trial: - You must be 18 years old or older - You must be willing and able to sign a consent form agreeing to take part - If you are not a healthy volunteer, you must have been diagnosed with a heart or blood vessel (cardiovascular) disease Who may not be able to join: - People who are cu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05658965 · University Hospital, Lille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 October 2026
🇫🇷 FR

Who might be able to join this trial: - Children under 1 year of age who are admitted for heart surgery using a heart-lung bypass machine at the CHU of Lille hospital during the study period. - Children who have a congenital heart condition (a heart problem present from birth) that requires surgery before the age of 1....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05662293 · University Hospital, Basel, Switzerland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇨🇭 CH

**Who might be able to join this trial:** *For the forward-looking (prospective) part of the study:* - You have been diagnosed with, or are suspected to have, a heart condition caused by an irregular heartbeat (arrhythmia-induced cardiomyopathy), based on your medical records or a referral from a heart or internal med...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05697861 · Intellia Therapeutics Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 1 March 2038
🇫🇷 FR🇳🇿 NZ🇸🇪 SE🇬🇧 GB

Who might be able to join this trial: - You previously took part in a clinical study run by Intellia and received all or part of a dose of the treatment called NTLA-2001 (whether you finished the study or left it early). - You have agreed to take part in this long-term follow-up study by signing a consent form. Who ma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05709132 · The Hospital for Sick Children Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 April 2027
🇨🇦 CA

**Who might be able to join this trial:** **As a mentee (younger participant):** - People who have been diagnosed with a heart condition - People who received their diagnosis at least 4 months ago - People between the ages of 12 and 17 years old - People who can speak and read English - People willing to commit to 5–1...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05731830 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇮🇹 IT

Who might be able to join this trial: - People who are 18 years of age or older. - People who have been diagnosed with TTS (Takotsubo Syndrome, a type of heart condition — confirm with trial site). - People for whom data about short-term and/or long-term exposure to air pollution is available. - People who are willing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05750147 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇬🇧 GB

Who might be able to join this trial: - Adults who are able to understand and agree to participate on their own behalf - Children whose parent or guardian is able to give consent on their behalf - People of any gender (male or female) - People who have been formally diagnosed with cardiomyopathy (a condition affecting...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05760924 · Tomsk National Research Medical Center of the Russian Academy of Scien... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇷🇺 RU

**Who might be able to join this trial:** - You are willing to follow the study rules and have signed a consent form agreeing to take part - You are between 18 and 80 years old (male or female) - You have been diagnosed with a type of heart failure caused by blocked arteries (ischemic) or another cause (non-ischemic) -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05761067 · Vastra Gotaland Region Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 September 2029
🇸🇪 SE

Who might be able to join this trial: - People who are older than 18 years of age - People whose heart is pumping at 40% or less of its normal capacity (a measurement called LVEF) - People who have a significant amount of blockages or narrowing in the arteries that supply blood to the heart, measured using a specific s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05769036 · Tomsk National Research Medical Center of the Russian Academy of Scien... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇷🇺 RU

**Who might be able to join this trial:** - You are willing to follow the study rules and have agreed in writing to take part - You are between 18 and 80 years old (male or female) - You have been diagnosed with heart failure caused by blocked arteries or another heart muscle problem - You have had heart failure sympt...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05793008 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 March 2026
🇮🇹 IT

**Who might be able to join this trial:** **For people with Takotsubo Syndrome (TTS) — a temporary heart condition often triggered by stress:** - Written consent has been provided by the patient, or by a parent, guardian, or legal representative on their behalf. - A diagnosis of TTS has been confirmed by a doctor usin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05818605 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 80 years old who have been diagnosed with hypertrophic cardiomyopathy (a condition where the heart muscle is thicker than normal), confirmed by a specific heart ultrasound measurement or by other supporting signs such as a family history of the conditio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05828719 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇰🇷 KR

**Who might be able to join this trial:** - People who are at least 19 years old - People who have been diagnosed with stage C heart failure and a weakened heart pump (where the heart is pumping less than 40% of its normal capacity) - People who have significant blockages in the arteries supplying the heart, confirmed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05835791 · Nova Scotia Health Authority Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2028
🇨🇦 CA

**Who might be able to join this trial:** - You have had a documented episode of a fast, abnormal heart rhythm (ventricular arrhythmia) lasting more than 30 seconds, confirmed by a heart monitor, ECG, defibrillator, or implanted device recording - This is your first time being diagnosed with this type of abnormal heart...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05836259 · Tenaya Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇺🇸 US

Who might be able to join this trial: - You have a specific gene change (mutation) in a gene called MYBPC3 - You have been diagnosed with a heart condition called hypertrophic cardiomyopathy (where the heart muscle becomes abnormally thick), either the type that blocks blood flow or the type that does not - Your heart...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05855746 · Assistance Publique - Hôpitaux de Paris Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 16 January 2028
🇫🇷 FR

**Who might be able to join this trial:** - Symptoms began 28 days ago or less - The condition first appeared with chest pain, signs of heart failure, and/or palpitations - A blood test result called troponin was above the normal upper limit at any point between hospital admission and enrolment in the trial - A heart...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05884892 · Magdi Yacoub Heart Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇪🇬 EG

Who might be able to join this trial: - People who have been diagnosed with hypertrophic cardiomyopathy (a condition where the heart muscle becomes abnormally thick) and are willing to give their consent to take part in the registry. - Family members of people diagnosed with hypertrophic cardiomyopathy who are willing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05885412 · Rocket Pharmaceuticals Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older at the time of signing the consent form - People who are able and willing to sign a consent form agreeing to take part - People who have been clinically diagnosed with ACM (arrhythmogenic cardiomyopathy) based on a specific set of recognised diagnosti...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05888662 · Rennes University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 October 2029
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 years or older - People undergoing their first radiofrequency ablation procedure for a type of irregular heartbeat (ventricular tachycardia) caused by ischaemic heart disease (reduced blood flow to the heart) - People who have an implanted defibrillator (ICD) w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05890716 · Idoven 1903 S.L. Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇳🇱 NL🇪🇸 ES

**Who might be able to join this trial:** - People who have had abnormal heart rhythms or unusual heart electrical patterns (such as fast heartbeats, irregular rhythms, or the heart stopping) that were recorded on a short-term heart monitor (ECG) with at least one recording channel. - People who have a suspected or co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05921279 · National University of Ireland, Galway, Ireland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇮🇪 IE

Who might be able to join this trial: - You are a woman aged 18 or older - You can read and understand English - You have been diagnosed with breast cancer (Stage I, II, or III) and are planned to receive chemotherapy as part of your treatment Who may not be able to join: - You are not receiving chemotherapy with the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05939700 · Bristol-Myers Squibb Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇺🇸 US

"Who might be able to join this trial: - You must have taken at least one dose of a medication called mavacamten at any point during pregnancy (including up to 4 months before becoming pregnant) or while breastfeeding (up to 12 months after the baby is born, or until you stopped breastfeeding, whichever happened first)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05942729 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇫🇷 FR

Who might be able to join this trial: - Adults who have had a heart ultrasound (echocardiography) that produced clear, good-quality images. Who may not be able to join: - People under 18 years of age. - People who are under legal protection measures, such as being under the care of a court-appointed guardian or curato...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05946772 · University Hospital Heidelberg Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2027
🇩🇪 DE

**Who might be able to join this trial:** - You are 18 years of age or older - You can be enrolled and receive the first dose of the study medication within 24 hours of having a heart catheter procedure - Your heart scan (either during the catheter procedure or on ultrasound) showed an abnormal pattern of heart wall mo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05961202 · Tongji Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2024
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 80 years old (male or female) - A heart scan (echocardiogram) done within the last 30 days showed that your heart's pumping function is below normal (less than 50%) - You have had heart failure for more than 6 months that has not improved with standard...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05965258 · The Cleveland Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

**Who might be able to join this trial:** - Your heart's pumping function (measured by a special heart scan called a cardiac MRI) shows that your heart is pumping at less than 55% of its normal capacity - You have a leaky mitral valve (a valve in your heart) that is at least moderately severe, confirmed by either a car...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05977049 · Weill Medical College of Cornell University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - You have been officially diagnosed with Takotsubo Syndrome (a type of heart condition sometimes called "broken heart syndrome") - You are over 18 years old Who may not be able to join: - You are already receiving psychotherapy (talk therapy) as part of your treatment for Takotsu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06010199 · First Affiliated Hospital Xi'an Jiaotong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2030
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with myocarditis (inflammation of the heart muscle) according to established medical criteria - People who are regularly attending follow-up appointments at a cardiovascular (heart) centre that is part of this trial **Who may not be able to joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06023186 · Michael Ayers Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign a written consent form agreeing to take part in the study - You are willing and able to attend scheduled appointments and follow the study procedures - You are a male or female between 18 and 85 years old - You have been diagnosed with a type...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06034405 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - People who have had spinal decompression surgery (a procedure to relieve pressure on the spine or nerves) within the past 20 years before joining the study. - People who were aged 50 or older at the time of that spinal surgery. - People who are able to understand and sign a conse...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06040242 · Swiss Federal Institute of Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇭 CH

**Who might be able to join this trial:** - You have been formally diagnosed with a heart condition called ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy) based on specific medical guidelines from 2010 - You carry a known or likely harmful change (variant) in one of three specific heart-related genes (PKP-2, DS...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06052475 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇬🇧 GB

Who might be able to join this trial: - People who already have a right-sided heart pacemaker, where the heart's pumping function (measured as a percentage called ejection fraction) is between 35% and 50%, and the pacemaker is being used heavily (more than 40% of the time) - People whose doctor has recommended upgradin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06060548 · Kansas City Heart Rhythm Research Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇺🇸 US

Who might be able to join this trial: - People who are older than 18 years of age - People who have a specific small heart monitor implanted under the skin called a Medtronic LINQ II ILR - People who are willing and able to sign a written consent form Who may not be able to join: - People who have had a heart attack i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06080074 · Stanford University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - The child is between 0 and 16 years old (under 17 years) - The child weighs between 3 and 80 kilograms - The child is using a specific type of heart-lung bypass machine called the Cardiohelp system, to support a failing heart (VA-ECMO) - This is the child's first time on this...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06082050 · Zhejiang University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 3 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years old at the time of signing the consent form. - People diagnosed with transthyretin cardiac amyloidosis (a condition where a protein called transthyretin builds up in the heart), either the inherited form or the age-related form, according to recogn...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06091475 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 August 2026
🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with dilated cardiomyopathy (a condition where the heart muscle is weakened and the heart becomes enlarged) - Your heart pumping function was previously measured as less than 40% (meaning the heart was not pumping well) - Your heart pumping function h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06092034 · Rocket Pharmaceuticals Inc. Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 1 April 2028
🇩🇪 DE🇮🇹 IT🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed to carry a harmful or likely harmful change (variant) in a gene called LAMP2 - People who are male - People who are 8 years of age or older - People whose heart shows abnormal thickening of the left ventricular wall (a part of the heart muscle)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06095466 · Post Graduate Institute of Medical Education and Research, Chandigarh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 August 2026
🇮🇳 IN

Who might be able to join this trial: - People who are between 18 and 65 years of age - People who have been diagnosed with cirrhosis (severe scarring of the liver), confirmed through clinical assessment, blood tests, tissue samples (when available), and ultrasound imaging - People with cirrhosis who are seriously ill...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06101108 · Philippe Debonnaire Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇧🇪 BE

Who might be able to join this trial: - You are 60 years old or older - You have a narrowing of the spinal canal in your lower back and are scheduled to have spine surgery - A tissue sample taken from a ligament in your spine (called the ligamentum flavum) during surgery shows a significant build-up of a protein deposi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06128980 · Herlev and Gentofte Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2028
🇩🇰 DK

**Who might be able to join this trial:** - You have been newly diagnosed with heart failure (either as an outpatient or during a hospital stay) where the heart is not pumping as strongly as it should (the pumping function is 40% or less on an ultrasound of the heart) - You have moderate to severe heart failure symptom...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06128993 · Royal Brompton & Harefield NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇬🇧 GB

Who might be able to join this trial: - You are having a specific type of heart attack called an "ST-elevation myocardial infarction" (or a similar equivalent condition, such as a newly detected heart rhythm problem called LBBB) - Your symptoms started less than 12 hours ago - The blood flow in the affected heart arter...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06129656 · University of Leipzig Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2033
🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with cardiac amyloidosis (a condition where abnormal proteins build up in the heart) confirmed by current medical standards Who may not be able to join: - You do not wish to take part in the trial Important: Always verify eligibility with the trial site...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06138873 · Rush University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 November 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older. - You have a heart condition caused by reduced blood flow to the heart muscle (known as ischemic cardiomyopathy). - You have had a documented episode of a specific type of fast, abnormal heart rhythm (called sustained monomorphic ventricular...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06143566 · University of Texas Southwestern Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with Type 2 diabetes - People who have chronic kidney disease at a moderate stage, meaning their kidneys are working at a reduced but not severely low level (confirmed by a specific kidney function measurement called eGFR, falling between 25 and 90)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06145035 · Roberto Bolli Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged between 21 and 85 years old - People who have been diagnosed with coronary artery disease (a significant blockage in at least one of the heart's main arteries), along with evidence of heart muscle damage, reduced heart pumping ability, and symptoms of heart failu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06146660 · Bristol-Myers Squibb Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇰🇷 KR

Who might be able to join this trial: - You must be 19 years of age or older - You must be taking the medication mavacamten as directed by its approved prescribing guidelines - You must be willing and able to sign a consent form agreeing to take part in the study Who may not be able to join: - You may not be eligible...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06158698 · Niguarda Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 2 May 2026
🇮🇹 IT

Who might be able to join this trial: - Men and women who have an inflammatory heart muscle disease linked to abnormal heart rhythms coming from the lower chambers, a weakened pumping function, or significantly raised levels of certain heart stress markers in the blood. - People aged 18 years or older. - People who hav...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06174220 · Hamilton Health Sciences Corporation Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2027
🇨🇦 CA

**Who might be able to join this trial:** - You have been found to carry a specific genetic change (variant) in one of these genes: PKP2, DSG2, DSC2, DSP, or JUP (note: JUP carriers must have the variant on both copies of the gene), OR you carry a specific variant called TMEM43-p.S358L (confirm with trial site) - A he...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06200311 · University Medical Center Groningen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 July 2029
🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with a type of heart condition involving an enlarged left atrial chamber (confirmed by a specific heart measurement) - People who have been confirmed through a heart tracing test (ECG) to have an irregular heart rhythm called atrial fibrillatio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06209359 · Yale University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2029
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with heart failure - Your doctors are not planning to change your heart failure medications or devices during the study - You have not had an unplanned hospital stay in the last 2 months - Your fluid levels are considered stable and well-controlled by...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06214507 · Rocket Pharmaceuticals Inc. Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2029
🇩🇪 DE🇮🇱 IL🇮🇹 IT🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** **For people joining the prospective (forward-looking) group:** - A certified genetic testing laboratory has confirmed a harmful or likely harmful change in the LAMP2 gene - The patient, or their parent or legal guardian, is able and willing to sign a consent form - The person...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06228924 · Tenaya Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2026
🇺🇸 US

**Who might be able to join this trial:** - You have a specific gene change (mutation) in the PKP2 gene that is known or likely to cause disease - You have been diagnosed with a heart condition called Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), based on specific medical guidelines from 2010 - Your heart's p...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06236022 · Tongji Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 70 years old. - You have been diagnosed with dilated cardiomyopathy, meaning your heart is enlarged and does not pump blood as well as it should, confirmed by heart imaging tests, and without severe blockages in your heart arteries or major heart valve prob...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06243653 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇰🇷 KR

**Who might be able to join this trial:** - You are at least 19 years old. - You have symptoms of heart failure (such as shortness of breath during activity or at rest) and your heart's pumping function is reduced (confirmed by a heart scan or test). - You already need a procedure called a coronary angiography (an imag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06250257 · Jimma University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 May 2026
Ethiopia

**Who might be able to join this trial:** - Women between the ages of 18 and 50 years old - People diagnosed with ischemic cardiomyopathy (heart muscle damage caused by reduced blood flow) or de novo dilated cardiomyopathy (a newly diagnosed condition where the heart muscle is weakened and enlarged) **Who may not be a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06251778 · Paolo Milani Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 January 2027
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with wild-type ATTR amyloidosis (a specific type of protein build-up disease that is not inherited) - People who are 18 years of age or older - People who have signs that the heart is affected, as shown by an ultrasound of the heart or a cardiac MRI...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06277297 · University of Cagliari Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with Takotsubo syndrome (a type of temporary heart condition, sometimes called "broken heart syndrome") according to specific European heart guidelines - People who are adults aged 18 or older - People who have had baseline clinical information reco...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06291805 · Steen Hvitfeldt Poulsen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇩🇰 DK

**Who might be able to join this trial:** **Group 1 – People with a specific type of heart condition called wild-type ATTR cardiac amyloidosis (wtATTR-CM):** - Adults over 18 years old who have been diagnosed with wtATTR-CM, either through a small tissue sample taken from the heart (endomyocardial biopsy), or through...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06311708 · Tenaya Therapeutics Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 29 March 2030
🇫🇷 FR🇩🇪 DE🇮🇹 IT🇸🇪 SE🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - People who are between 14 and 65 years old at the time of signing consent - People who have a confirmed harmful or likely harmful change (mutation) in the PKP2 gene - People who have been diagnosed with a heart condition called ARVC, meeting a specific set of diagnostic guideline...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06327308 · Centre Hospitalier Universitaire de Besancon Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 11 March 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who have liver cirrhosis and are being considered for a liver transplant, with no medical reasons ruling out transplantation - Women who have gone through menopause at least 24 months ago, have had a surgical procedure that prevents pregnancy, or are using an effectiv...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06332859 · Pensionsversicherungsanstalt Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 October 2026
🇦🇹 AT

**Who might be able to join this trial:** - You have been diagnosed with Takotsubo cardiomyopathy (sometimes called "broken heart syndrome") or have had a heart attack within the last 6 months - You are older than 18 years of age - You are willing and able to sign a consent form agreeing to take part **Who may not be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06350994 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇫🇷 FR

Who might be able to join this trial: - You must have received CAR-T cell therapy (a type of cancer treatment) between 3 and 5 days before having a heart ultrasound (echocardiography) done as part of this study. - You must have already had a heart ultrasound and a heart tracing test (EKG/ECG) done before starting your...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06352307 · First Affiliated Hospital Xi'an Jiaotong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2030
🇨🇳 CN

Who might be able to join this trial: - You must be over 18 years old. - You must have been diagnosed with ACM (a heart condition called Arrhythmogenic Cardiomyopathy), confirmed through tests such as a heart ultrasound, electrocardiogram (ECG), heart scan (MRI), tissue examination, and genetic testing. - You (or a fam...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06352320 · First Affiliated Hospital Xi'an Jiaotong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2030
🇨🇳 CN

Who might be able to join this trial: - You must be over 18 years old. - You must have been diagnosed with a heart muscle disease (cardiomyopathy), confirmed through tests such as a heart ultrasound, ECG (heart tracing), MRI scan, tissue examination, or genetic testing. - You (or a family member on your behalf) must ag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06356727 · Azienda Ospedaliera Universitaria Integrata Verona Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2026
🇮🇹 IT

**Who might be able to join this trial:** - Adults (male or female) aged 18 or older - People who have recently been diagnosed for the first time with a type of heart condition called idiopathic dilated cardiomyopathy (a weakened, enlarged heart with no known cause), where the heart's pumping function is significantly...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06368518 · Medical University of Graz Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2044
🇦🇹 AT

Who might be able to join this trial: - People who attend the outpatient clinic for hypertrophic cardiomyopathy (a type of heart muscle thickening) at one of the participating medical centres that are part of the HCM Registry - People whose heart wall measurement (the wall between the two lower chambers of the heart) m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06371937 · London Health Sciences Centre Research Institute OR Lawson Research In... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2033
🇨🇦 CA

Who might be able to join this trial: - Adults between 18 and 80 years of age - People who have been diagnosed with Cardiovascular Disease (a condition affecting the heart and blood vessels) - People who have been diagnosed with Cerebrovascular Disease (a condition affecting blood flow to the brain) - People who have b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06381778 · Far Eastern Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇹🇼 TW

**Who might be able to join this trial:** - Your heart scan (echocardiogram or MRI) shows that certain walls of your heart are thickened — specifically, the wall between the two lower chambers or the back wall of the heart measures 13mm or more - The tip (apex) of your heart wall measures 15mm or more, OR the tip of th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06405750 · University Hospital Bispebjerg and Frederiksberg Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2035
🇩🇰 DK

Who might be able to join this trial: - People who have given their signed agreement to take part in the trial - People who are scheduled to have open-heart surgery, including coronary artery bypass grafting (a procedure to improve blood flow to the heart), heart valve repair or replacement, surgery on the main artery...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06409585 · University of Edinburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇬🇧 GB

Who might be able to join this trial: **General requirements (apply to all groups):** - People aged between 30 and 90 years old, male or female - People who are willing and able to give their signed agreement to participate before any study procedures begin **Heart failure with preserved pumping function (HFpEF) grou...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06412666 · Cytokinetics Phase 3 · 6 countries Recruiting
Recruiting Phase 3 Est. completion 1 January 2030
🇨🇦 CA🇮🇹 IT🇯🇵 JP🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who are aged 12 and under 18 years old at the time of screening and at the start of the trial. - People who weigh at least 45 kg (for the first group of participants), or at least 35 kg once the trial has confirmed safety data from at least 10 earlier participants. -...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06427226 · Tanta University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇪🇬 EG

**Who might be able to join this trial:** - People aged 18 years or older - People who have never received chemotherapy before and have a biopsy-confirmed diagnosis of breast cancer at stage I, II, or III - People whose treatment plan includes at least 4 cycles of a chemotherapy drug called doxorubicin - People who ar...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06431919 · Post Graduate Institute of Medical Education and Research, Chandigarh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2028
🇮🇳 IN

**Who might be able to join this trial:** - People between 18 and 65 years of age - People who have been diagnosed with compensated cirrhosis (a form of liver scarring where the liver is still managing to function), confirmed through a liver biopsy, blood tests, or ultrasound scan - People whose heart scans (a type of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06433050 · University of Pennsylvania Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older, of any sex - People who are willing and able to sign a consent form agreeing to take part in the study - People who are available for the full length of the study and willing to follow all study procedures - People who are able to swallow tablets and...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06446271 · NHS Greater Glasgow and Clyde Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 March 2027
🇬🇧 GB

**Who might be able to join this trial:** - You are aged 10 years or older (male or female) - You are able to provide written agreement to take part (or a parent/guardian can do so on your behalf if you are younger) - You have a known or likely harmful change (variant) in one of five specific heart muscle genes (TTN, L...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06464588 · Emory University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2027
🇺🇸 US

Who might be able to join this trial: - People aged 16 years and older but under 40 years old (for Phase 1A of the trial). - People aged 4 years and older but under 16 years old (for Phase 1B of the trial). - People in Phase 1A must be able to sign their own consent form. - People who have been diagnosed with dilated c...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06474819 · Institut d'Investigació Biomèdica de Bellvitge Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 January 2027
🇪🇸 ES

Who might be able to join this trial: - You are receiving your first ever pacemaker (either a single- or dual-chamber device) because your heart beats too slowly due to a serious electrical conduction problem between the upper and lower chambers of the heart, or because you have an irregular heart rhythm (atrial fibril...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06481891 · Lexicon Pharmaceuticals Phase 3 · 19 countries Recruiting
Recruiting Phase 3 Est. completion 1 July 2026
🇦🇷 AR🇧🇪 BE🇧🇷 BR🇧🇬 BG🇭🇷 HR🇨🇿 CZ🇫🇷 FR🇬🇪 GE +11 more

**Who might be able to join this trial:** - People whose heart condition is significantly affecting their quality of life, based on a specific symptom score (called the KCCQ CSS) of less than 85 - People whose heart condition limits their physical activity to a moderate or slight degree (known as NYHA Class II or III)...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06490250 · Istanbul University - Cerrahpasa Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2025
Turkey (Türkiye)

**Who might be able to join this trial:** - The wall of your heart's main pumping chamber is thickened (15mm or more), as shown on an ultrasound or MRI scan of the heart - You are in a stable condition with mild or no symptoms of heart failure (able to do light activity without major discomfort) - You are 18 years of a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06506071 · Salamanca University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2024
🇪🇸 ES

Who might be able to join this trial: - You are 18 years of age or older - You have been admitted to hospital because of chest pain and signs of heart muscle damage - Your doctor has recommended a cardiac MRI because you may have had a heart attack with no major blockages in your arteries, heart muscle inflammation, or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06512571 · China National Center for Cardiovascular Diseases Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People whose heart has a thickened wall of 13mm or more (measured by ultrasound of the heart at a specific point in the heart's pumping cycle) - People who have at least two or more "warning signs" linked to a condition called Fabry Disease (FD) — these warning signs can be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06539208 · YolTech Therapeutics Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years old (any gender) - People who weigh between 40 and 90 kg at the time of screening - People who have had a TTR gene mutation confirmed through genetic testing - People whose liver function blood test results (AST, ALT, and bilirubin) are within the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06542016 · Shenzhen Second People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 or older, of any gender or ethnicity - People who have been diagnosed with stage 5 chronic kidney disease (the most advanced stage of kidney failure), based on established medical guidelines - People who are newly diagnosed with kidney failure and are planning to s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06546137 · Hospital do Coracao Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇧🇷 BR

Who might be able to join this trial: - People who have been clinically diagnosed with a hereditary cardiovascular disease, based on current medical guidelines - People who agree to receive genetic counseling as part of the trial - People who are willing to sign a consent form agreeing to take part - People who are abl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06551129 · Bristol-Myers Squibb Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older. - You have been prescribed a medication called mavacamten for a heart condition called obstructive hypertrophic cardiomyopathy (a thickening of the heart muscle that blocks blood flow). - You are willing and able to give your consent to take part...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06555237 · Medical University of Warsaw Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇵🇱 PL

Who might be able to join this trial: - You (or your child) have been diagnosed with a RASopathy (a group of genetic conditions affecting growth and development) - You (or your child) have been diagnosed with hypertrophic cardiomyopathy (a condition where the heart muscle becomes thickened) - You (or your child's guard...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06556485 · Heart and Diabetes Center North-Rhine Westfalia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇩🇪 DE

**Who might be able to join this trial:** - People who have heart failure caused by reduced blood flow to the heart, where the heart's pumping strength is 35% or less (measured within the 6 weeks before joining the trial) - People who have been assessed as eligible for a heart transplant due to severe heart failure - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06564909 · Ain Shams University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are a male or female between the ages of 18 and 75 years old - You have had a specific type of heart attack called a STEMI and are receiving a procedure to open the blocked artery (called PCI or coronary angioplasty) **Who may not be able to join:** - You have had a prev...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06570902 · Zoll Medical Corporation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2029
🇩🇪 DE

Who might be able to join this trial: - People who had their first-ever coronary artery bypass graft (heart bypass) surgery less than 10 days before joining the study. - People whose doctor prescribed a wearable defibrillator vest (a device worn on the body that can detect and treat dangerous heart rhythms) primarily b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06575881 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who were diagnosed with an irregular heart rhythm condition — either atrial fibrillation (AF), frequent extra heartbeats from the lower heart (PVCs), or a fast abnormal heart rhythm (VT) — before the age of 60 - People who are already schedule...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06580717 · Yonsei University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 November 2026
🇰🇷 KR

**Who might be able to join this trial:** - People who have read and understood the research protocol and have signed a consent form - Adults aged 20 to 79 years old - People who do not have diabetes, or people who have type 2 diabetes with a blood sugar control measure (HbA1c) between 6.5% and 10.5% - People diagnose...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06591260 · Scientific Institute San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇮🇹 IT

Who might be able to join this trial: - You (or your child's guardian) must be willing to sign a written consent form to take part. - The patient must be under 18 years old (a child or young person). - The patient must be suspected by doctors of having myocarditis (inflammation of the heart muscle). - The patient must...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06593327 · University of Texas Southwestern Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 December 2027
🇺🇸 US

Who might be able to join this trial: - You are a primary care provider (such as a doctor or nurse practitioner) who sees patients with diabetes in your clinic Who may not be able to join: - You are a healthcare provider who does not see patients with diabetes in your practice Important: Always verify eligibility wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06607471 · Scientific Institute San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2035
🇮🇹 IT

Who might be able to join this trial: - People who have given written agreement to take part (for children, a parent or guardian must provide this consent on their behalf, following the rules of the country where the trial takes place) - People who are suspected of having, have been diagnosed with, or have a genetic pr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06620705 · srdpiers Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇩🇰 DK🇳🇱 NL

**Who might be able to join this trial:** - You are 18 years old or older and have a permanent irregular heart rhythm (called atrial fibrillation) along with a heart that pumps less efficiently than normal (less than 50% of its capacity) - You either need electrical pacing to keep your heart from beating too slowly (in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06632834 · National Taiwan University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 19 January 2025
🇹🇼 TW

**Who might be able to join this trial:** - People diagnosed with dilated cardiomyopathy (a condition where the heart is enlarged and weakened) whose heart is still not pumping well enough, even with treatment, as confirmed by specific heart scan measurements - People whose heart condition is classified as moderately...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06634108 · London Health Sciences Centre Research Institute OR Lawson Research In... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2025
🇨🇦 CA

**Who might be able to join this trial:** - People between 40 and 80 years old. - People who have heart failure with a weakened heart pump (where the heart is pumping less blood than normal), caused either by blocked arteries or other reasons, confirmed by a heart scan showing the pumping function is below 40%. - Peop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06644742 · Rocket Pharmaceuticals Inc. Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇳🇱 NL🇺🇸 US

**Who might be able to join this trial:** - You are 12 years old or older at the time of signing the consent form - You are able and willing to sign a consent form and follow the study's rules and requirements - You have been diagnosed with a heart condition called arrhythmogenic cardiomyopathy (ACM), a disease affecti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06646601 · Assistance Publique Hopitaux De Marseille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are over 18 years old - You live within approximately 20 km of Gap, Laragne-Montéglin, Veynes, or Clermont-Ferrand in France - You have been personally invited to take part by staff at a medical facility involved in the trial - You have been diagnosed with one of the foll...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06660732 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a consent form and follow the study rules - People aged 18 to 80 years old - Women who are postmenopausal (no periods for at least 12 months), have had a hysterectomy, both ovaries or fallopian tubes removed...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06661876 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇧🇪 BE

Who might be able to join this trial: - People aged 18 or older - People with advanced heart failure that has not responded well to treatment, rated as Class II, III, or IV on a standard heart failure severity scale - People whose heart failure has been stable for the last 6 months and who are already on the maximum re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06669962 · A.O.U. Città della Salute e della Scienza Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 June 2026
🇮🇹 IT

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with Takotsubo syndrome (a type of temporary heart condition, sometimes called "broken heart syndrome") - People who are willing to sign a consent form agreeing to take part in the study Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06688396 · Lancaster General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** **For the main patient (called the "Proband"):** - You are 18 years of age or older - A doctor has confirmed you have a specific type of heart condition called non-ischemic dilated cardiomyopathy (a weakened, enlarged heart not caused by blocked arteries), where your heart's p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06699056 · Peerbridge Health, Inc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 November 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who are able and medically suitable to wear a Holter monitor (a small portable heart recording device) Who may not be able to join: - People who are using mechanical support for breathing, heart circulation, or kidney function at the time o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06703489 · Medtronic Cardiac Ablation Solutions Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have had a heart attack that caused scarring of the heart muscle (ischemic cardiomyopathy), or people with heart muscle scarring from a non-blockage-related cause confirmed by heart imaging (non-ischemic cardiomyopathy). - People who have had at least one episode...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06711185 · University of Campinas, Brazil Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 January 2026
🇧🇷 BR

Who might be able to join this trial: - People who are female - People who are over 18 years old - People who have been diagnosed with breast cancer - People whose treatment plan includes chemotherapy, with a planned total dose equivalent to 240 mg/m2 of doxorubicin (a specific chemotherapy drug) Who may not be able t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06730464 · Centro Medico Teknon Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 30 October 2026
🇮🇹 IT🇵🇹 PT🇪🇸 ES

**Who might be able to join this trial:** - You have been diagnosed with a non-ischemic heart condition affecting the left side of your heart, specifically dilated cardiomyopathy (an enlarged heart), non-dilated left ventricular cardiomyopathy (a heart muscle disease without enlargement), or cardiomyopathy that develop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06730607 · Centro Medico Teknon Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇮🇹 IT🇪🇸 ES

**Who might be able to join this trial:** - People who are older than 18 years of age - People who were diagnosed with myocarditis (inflammation of the heart muscle) more than 6 months before joining the study - People who have had a specific type of heart scan (called a CMR scan) performed more than 6 months after the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06734689 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 January 2028
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with cancer and have been receiving immune checkpoint inhibitor (ICI) treatment for at least 3 months, with at least 2 doses received, and who have not developed any new heart or muscle symptoms, abnormal heart test (ECG) results, abnormal hear...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06741995 · Union Hospital, Tongji Medical College, Huazhong University of Science... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any gender - People who have been diagnosed with dilated cardiomyopathy - People (or their legal guardians) who are willing to participate voluntarily and sign a consent form after being fully informed about the study and its risks **Who may no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06742008 · Union Hospital, Tongji Medical College, Huazhong University of Science... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with VMC (confirm with trial site for full diagnosis details) - Your symptoms started no more than 30 days ago - You are between 18 and 75 years old - You (or your legal guardian) are willing to be fully informed about the study, join voluntarily, and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06747429 · Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos I... Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇫🇷 FR🇮🇹 IT🇷🇴 RO🇪🇸 ES

Who might be able to join this trial: - Adults aged 18 or older, of any sex. - People who have been diagnosed with heart failure caused by a condition called non-ischemic dilated cardiomyopathy (a type of weakened, enlarged heart not caused by blocked arteries), with or without a known genetic cause. - People whose hea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06776419 · Caroline Michaela Kistorp Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇩🇰 DK

**For patients with Fabry disease:** Who might be able to join this trial: - You have been diagnosed with Fabry disease confirmed by genetic testing - You are 18 years of age or older - You are able to understand and sign a consent form agreeing to take part Who may not be able to join: - You have a condition that ma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06793020 · Vilnius University Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇱🇹 LT🇵🇱 PL

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with sepsis (a serious response to infection) based on specific medical scoring criteria, meaning they have a suspected or confirmed infection along with signs that their organs are under stress - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06800716 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a type of heart disease called dilated cardiomyopathy, where the heart is enlarged and pumping very poorly (confirm with trial site for specific measurements) - Your doctor has decided you need temporary mechanic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06804278 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years old or older - You have come in with sudden chest pain and your doctor has recommended a specific CT scan (either a "triple-rule-out" CT or a heart CT scan) because there is a low or moderate chance you may have an acute heart/coronary artery problem - Your E...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06814587 · University of Texas Southwestern Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

Who might be able to join this trial: **For people with ischemic heart disease (heart disease caused by blocked arteries):** - Adults between 18 and 80 years old (male or female) - People who have been scheduled for coronary artery bypass graft (CABG) heart surgery as part of their regular medical care - People who ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06814990 · Stephanie Gräger Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 April 2027
🇩🇪 DE

Who might be able to join this trial: - Adults aged 18 to 99 years old - People who have given written consent to participate - People who have been diagnosed with decompensated liver cirrhosis (a serious stage of liver scarring where the liver is no longer functioning well), confirmed through clinical assessment, imag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06816251 · Shandong Suncadia Medicine Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 85 years old (inclusive), either male or female - Your body mass index (a measure of body weight relative to height) is below 35 kg/m² - You understand what the study involves, are willing to take part, and can sign a consent form - If you are a woman w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06818760 · The Cleveland Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

Who might be able to join this trial: - You are a woman who has been seen in a cardio-obstetrics clinic (a clinic that manages heart conditions during pregnancy) before, during, or after pregnancy - You have been diagnosed with a congenital heart disease (a heart condition you were born with) that falls into a moderate...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06836011 · Medical University of Vienna Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇦🇹 AT🇩🇪 DE🇮🇹 IT🇳🇱 NL

Who might be able to join this trial: - People who have been diagnosed with a heart condition called ATTR cardiomyopathy (a disease where a protein called transthyretin builds up in the heart muscle) - People who have had a detailed heart ultrasound (echocardiogram) done within 6 months before or after their diagnosis,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06845319 · Medical University of South Carolina Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of breast cancer called triple-negative breast cancer (TNBC), or a hormone receptor-low invasive breast cancer, at Stage II or Stage IIIA/B (meaning the cancer is locally advanced but has not spread to distant parts of the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06846086 · Tanta University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are 18 years old or older and have been diagnosed with a heart muscle disease (cardiomyopathy), confirmed by tests such as an ultrasound of the heart or other imaging. - Your condition is stable and you are already taking standard medications for cardiomyopathy, such as A...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06866912 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2033
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with a condition called amyloidosis (a disease where abnormal proteins build up in the body's organs and tissues) - You carry a gene change (mutation) in the transthyretin gene but do not yet have symptoms - You are at least 18 years old at the time of you...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06887140 · University Medical Center Ho Chi Minh City (UMC) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇻🇳 VN

Who might be able to join this trial: - People who have been diagnosed with sepsis (a serious infection-related illness affecting the whole body) - People who received care in the Intensive Care Unit (ICU) at the University Medical Center in Ho Chi Minh City during the study period Who may not be able to join: - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06887283 · University Hospital, Essen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇩🇪 DE

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with, or your doctor suspects you may have, amyloidosis (any type) - You are willing and able to sign a written consent form to take part in the study **Who may not be able to join:** - You are under 18 years of age...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06889662 · Scientific Institute San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with myocarditis (inflammation of the heart muscle), confirmed by a heart tissue biopsy and/or a special type of heart MRI scan - You are 10 years old or older - You are willing to have your heart rhythm monitored remotely using an ECG device - You have gi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06896266 · Hospital Universitario 12 de Octubre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇪🇸 ES

Who might be able to join this trial: - You have atrial fibrillation or atrial flutter that does not go away on its own. - You have had a heart imaging test (such as an echocardiogram, MRI, or CT scan) during your heart rhythm problem that showed your heart's pumping strength (called ejection fraction) is below 50%, an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06898723 · First Affiliated Hospital of Wannan Medical College Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with septic shock (a life-threatening condition where an infection causes dangerously low blood pressure and organ problems), diagnosed using the "Sepsis 3.0" medical guidelines - You are 18 years old or older **Who may not be able to join:** - You ar...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06898762 · Fundacion para la Formacion e Investigacion Sanitarias de la Region de... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇪🇸 ES

Who might be able to join this trial: - People who have had chest pain that feels like it is coming from around the heart or that resembles a heart attack. - People who have had shortness of breath during activity or at rest for up to 3 months. - People who have had shortness of breath during activity or at rest lastin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06902896 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old who have been diagnosed with dilated cardiomyopathy (a condition where the heart muscle is weakened and enlarged). - People who are able to confirm they understand the risks, benefits, and treatment options involved, and who (or whose...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06907186 · Fondazione IRCCS Policlinico San Matteo di Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇮🇹 IT

Who might be able to join this trial: - People who are at least 18 years old - People who are fluent in Italian - People who are a patient, a presymptomatic carrier, or a caregiver of someone with ATTRv (a hereditary form of amyloidosis), and who are under the care of the Amyloidosis Center at Fondazione IRCCS Policlin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06920030 · Berlin Heals GmbH Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
Bosnia and Herzegovina🇷🇸 RS

**Who might be able to join this trial:** - People diagnosed with idiopathic dilated cardiomyopathy (a type of heart disease where the heart muscle is weakened for no known reason) who still have significant symptoms despite receiving proper heart failure treatment, classified as NYHA class III or IV (meaning moderate...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06922851 · Union Hospital, Tongji Medical College, Huazhong University of Science... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with dilated cardiomyopathy (a condition where the heart is enlarged and cannot pump blood well) - People who have a specific antibody in their blood called an anti-β1-adrenergic receptor antibody (confirm with trial site) - People between 18 an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06922994 · Centro Cardiologico Monzino Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2026
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years of age or older at the time of signing the consent form - You have been diagnosed with Arrhythmogenic Cardiomyopathy (a specific heart condition) based on established medical criteria **Who may not be able to join:** - You have a known allergy or sensitivity...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06930092 · Seoul National University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2028
🇰🇷 KR

**Who might be able to join this trial:** - People aged 19 years or older - People who are able to verbally confirm they understand the risks, benefits, and alternatives of the procedures involved, and who (or whose legal representative) can provide written consent before any study procedures begin - People whose hear...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06935253 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇺🇸 US

Who might be able to join this trial: - You must be a fully qualified or in-the-process-of-qualifying heart specialist doctor (cardiologist). Who may not be able to join: - You may not be able to join if you are not currently seeing and treating patients in a clinical setting. Important: Always verify eligibility wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06949748 · University of Athens Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇬🇷 GR

**Who might be able to join this trial:** - You have frequent extra heartbeats (called PVCs) that happen on their own, with no known cause, making up more than 5% of your heartbeats on multiple 24-hour heart monitor recordings - Your heart's structure and function appear normal on an ultrasound of the heart (echocardi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06954103 · Chensheng Pan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who were admitted to hospital within 48 hours of their stroke symptoms starting, where a CT or MRI scan has confirmed they had a stroke (either a blocked blood vessel or a bleed in the brain) - People whose stroke has been rated as moderate to severe, based on a standa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06964464 · University of Rochester Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 June 2031
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You have an implanted defibrillator device (ICD) that was placed to prevent a first serious heart event, due to heart failure with reduced pumping ability, and your device can be monitored remotely - You are currently taking a heart medication c...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06965621 · Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceut... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 October 2026
🇺🇸 US

Who might be able to join this trial: - You have heart failure caused by reduced blood flow to the heart (ischemic cardiomyopathy) that is currently stable - Your heart's pumping ability is significantly reduced, meaning tests show your heart pumps out 35% or less of blood with each beat - You have had an implanted def...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06976606 · Lexeo Therapeutics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇺🇸 US

Who might be able to join this trial: - Adults who have been diagnosed with a heart condition called arrhythmogenic cardiomyopathy (ACM), based on a specific set of recognised medical guidelines from 2010. - People who have a confirmed genetic change in a gene called PKP2 that is known or likely to cause disease. - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06978998 · Yonsei University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 December 2030
🇰🇷 KR

Who might be able to join this trial: - People between 20 and 79 years old whose heart is pumping less efficiently than normal (the heart pumps out 40% or less of its blood with each beat, as measured by an ultrasound of the heart), and who are able to give written agreement to take part in the study voluntarily. Who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07006493 · SuZhou Sinus Medical Technologies Co.,Ltd Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 80 years old (any sex) - You have been diagnosed with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thickened and blocks blood flow) - You have noticeable symptoms such as shortness of breath, chest pain, tiredness, hear...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07009639 · University of Calabria Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇮🇹 IT

Who might be able to join this trial: - People between 18 and 85 years of age - People who are currently admitted to a Cardiac Care Unit (a specialised hospital ward for serious heart conditions) due to an acute heart problem, such as a heart attack, heart failure, or dangerous irregular heartbeats - People who are abl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07021963 · Shandong Suncadia Medicine Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

Who might be able to join this trial: - You have a heart condition called hypertrophic cardiomyopathy (a thickened heart muscle) and have already taken part in a previous study related to a drug called HRS-1893. - If you are a woman who could become pregnant, you must have a negative pregnancy test within 7 days before...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07021976 · Shandong Suncadia Medicine Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2026
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 85 years old, of any gender - People with a Body Mass Index (BMI) below 35 (a measure of body weight relative to height) - People who have been diagnosed with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is abnormally thick and...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07023614 · Imbria Pharmaceuticals, Inc. Phase 2 · 11 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇦🇹 AT🇧🇪 BE🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇵🇱 PL🇵🇹 PT +3 more

Who might be able to join this trial: - People who have been clinically diagnosed with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes abnormally thick, in line with recognised medical guidelines - People whose specific type of HCM (non-obstructive HCM) has been confirmed through ultrasoun...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07026708 · University Hospital Centre Mother Teresa Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
Albania

Who might be able to join this trial: - People aged 18 to 85 years who have been diagnosed with a type of heart condition called Acute Coronary Syndrome (ACS) and are having a procedure to open blocked heart arteries (called PCI) in the cardiology department or cardiac intensive care unit. Who may not be able to join:...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07054073 · Christopher Kramer Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You were part of the original HCMR study group - You are between 18 and 65 years old (male or female) - **If you have the obstructive type of HCM (thickened heart muscle that blocks blood flow):** Your body weight relative to height (BMI) is under 35, and tests show that blo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07076615 · May Mohamed Abdalla Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 May 2026
🇪🇬 EG

**Who might be able to join this trial:** - People aged 18 or older - People who have been hospitalised or visited an emergency department due to acute (sudden or worsening) heart failure, diagnosed according to recognised international guidelines, based on typical symptoms and signs - People with blood test results sh...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07077005 · Technical University of Munich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇩🇪 DE

Who might be able to join this trial: - You must be 18 years of age or older - You must have been diagnosed with a heart condition called hypertrophic obstructive cardiomyopathy (a thickening of the heart muscle that blocks blood flow) - You must have been taking the same dose of a medication called mavacamten for at l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07079605 · Jimma University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 May 2026
Ethiopia

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with sepsis and admitted to Jimma University Medical Center during the study period - People who are willing to take part in the study and agree to have their condition monitored for at least one year Who may not be able to join: -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07086144 · Azienda Ospedaliero, Universitaria Ospedali Riuniti Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇮🇹 IT

Who might be able to join this trial: - Children and teenagers under 18 years old who have been diagnosed with myocarditis (inflammation of the heart muscle) that is also causing irregular heartbeats or problems with how well the heart is pumping Who may not be able to join: - Children whose parents or legal guardians...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07103057 · Viz.ai, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older at the time you arrive at the healthcare facility - You have had a resting heart tracing test (ECG) that was flagged by a computer system called Viz HCM as possibly showing a heart condition called HCM (hypertrophic cardiomyopathy) - You may qual...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07110818 · Montreal Heart Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2030
🇨🇦 CA

**Who might be able to join this trial:** - Your heart's pumping function (measured as a percentage called LVEF) is below 50% - Your heart's pumping function is between 50–55%, AND scans show specific changes to your heart tissue or an enlarged heart chamber, AND you carry a gene change known to cause a type of heart...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07116525 · Biosense Webster, Inc. Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇧🇪 BE🇫🇷 FR🇱🇹 LT

**Who might be able to join this trial:** - You have been diagnosed with, and your doctor has recommended, a heart procedure called catheter ablation to treat an irregular heartbeat — specifically ventricular tachycardia, premature ventricular complexes, atrial tachycardia, or atrial fibrillation (having had a previou...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07120776 · University of Manchester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2028
🇬🇧 GB

Who might be able to join this trial: - People aged 18 or older who have given written agreement to take part. - People who have been diagnosed with a heart condition called Hypertrophic Obstructive Cardiomyopathy (HOCM), where the heart muscle is abnormally thick (at least 15mm) and blood flow out of the heart is part...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07137338 · Rocket Pharmaceuticals Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2029
🇺🇸 US

Who might be able to join this trial: - People aged 18 to 65 years old at the time of signing the consent form - People who are willing and able to sign a consent form agreeing to take part - People diagnosed with dilated cardiomyopathy (a condition where the heart is enlarged and does not pump well), with a heart pump...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07145138 · University of Illinois at Chicago Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

Who might be able to join this trial: - People who are at least 18 years old and are being treated at or visiting a UIH (University of Illinois Health) location. - People who are willing and able to sign a written consent form agreeing to take part in the trial. Who may not be able to join: - Adults who are not able t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07150299 · Medical University of Vienna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇦🇹 AT

**Who might be able to join this trial:** - Adults aged 18 years or older - People diagnosed with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thickened and blocks blood flow) according to specific 2023 medical guidelines - People who already have a cardiac MRI scan with a special type...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07202897 · Rennes University Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 7 January 2032
🇫🇷 FR

**Who might be able to join this trial:** - You are between 40 and 80 years old - You weigh between 50 and 120 kg (approximately 110 to 265 lbs) - Your heart is beating in a normal, regular rhythm (called "sinus rhythm") - You have previously been diagnosed with a specific heart condition called "primary" hypertrophic...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07210723 · Kardigan, Inc. Phase 3 · 11 countries Recruiting
Recruiting Phase 3 Est. completion 1 September 2027
🇧🇪 BE🇩🇰 DK🇫🇷 FR🇭🇺 HU🇮🇹 IT🇳🇱 NL🇵🇱 PL🇪🇸 ES +3 more

Who might be able to join this trial: - People who have been diagnosed with dilated cardiomyopathy (an enlarged, weakened heart) linked to specific genetic variants (in genes called MYH7, TTN, or similar), or where the condition runs in the family - People whose heart failure symptoms fall into a moderate-to-severe ran...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07215715 · eMyosound SAS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** **Criteria that apply to all three groups:** - People aged 60 years or older - People who are willing and able to sign a consent form and follow the study requirements **Criteria for people with heart failure (with a heart pumping function above 40%), with or without a condit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07218887 · Alexion Pharmaceuticals, Inc. Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 27 January 2032
🇮🇹 IT🇪🇸 ES🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You have a specific gene change (mutation) in a gene called BAG3 that is known or likely to cause health problems - You have been diagnosed with a type of heart condition called dilated cardiomyopathy (DCM), where the heart is enlarged and does not pump well - You are on a stable...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07223242 · University of Texas Southwestern Medical Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older - People whose heart is pumping at a normal or preserved rate (a measure called LVEF of 50% or higher) - People who have been diagnosed with a type of heart failure called HFpEF — meaning they were admitted to hospital for heart failure in the p...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07224178 · University of Pittsburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults between the ages of 18 and 80 who had a full heart ultrasound (echocardiogram) at UPMC Presbyterian Echocardiography Lab, referred because of a suspected stroke - People who have been formally diagnosed with a stroke by a specialist stroke doctor - People whose heart...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07240844 · Seoul St. Mary's Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 29 April 2027
🇰🇷 KR

**Who might be able to join this trial:** - You are 19 years of age or older - You have been diagnosed with amyloid cardiomyopathy (a heart condition caused by abnormal protein deposits), confirmed by a heart tissue sample or special imaging tests - You have heart failure symptoms that are moderate — meaning you feel...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07241104 · AstraZeneca Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 22 November 2027
🇳🇱 NL

Who might be able to join this trial: - You must be between 18 and 80 years old at the time of screening - You must have already tested positive for a specific genetic change called the R14 del PLN mutation - Your heart's pumping ability (measured by an ultrasound of the heart) must show the heart is pumping out 45% or...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07245420 · St. Jude Children's Research Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2029
🇺🇸 US

Who might be able to join this trial: - People who are participants in the Childhood Cancer Survivor Study (CCSS) - People who are 26 years of age or older - People who were treated for childhood cancer with a certain level of heart-affecting chemotherapy drugs called anthracyclines (at a cumulative dose of 100 mg/m² o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07250529 · University Hospital of Patras Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 April 2029
🇬🇷 GR

**Who might be able to join this trial:** - You are 18 years of age or older - You are scheduled to have a dual-chamber pacemaker implanted because of a permanent complete or significant partial blockage in the heart's electrical system (called complete heart block or second-degree AV block) - Your heart's pumping stre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07263204 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇳 CN

Who might be able to join this trial: - You must be an adult aged 18 or older. - For the main heart condition group: You have been diagnosed with a condition called hypertrophic cardiomyopathy (a thickened heart muscle) according to specific Chinese medical guidelines from 2023. - For the "similar condition" group: An...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07265349 · Tasly Pharmaceutical Group Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 80 years, of any gender - People whose doctors have determined that coronary artery bypass graft (CABG) heart surgery is an appropriate treatment for long-term reduced blood flow to the heart - People whose heart pumping strength (measured by echoc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07286643 · Post Graduate Institute of Medical Education and Research, Chandigarh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2028
🇮🇳 IN

**Who might be able to join this trial:** - You have cirrhosis (scarring of the liver), from any cause, and are seriously ill - Your blood pressure has dropped to a dangerously low level as a result of a serious infection (sepsis) - You are between 18 and 65 years old **Who may not be able to join:** - You are already...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07293338 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with dilated cardiomyopathy (an enlarged heart) confirmed by an ultrasound of the heart, where the heart's main pumping chamber measures more than 55 mm in men or more than 50 mm in women. - People who have signs and symptoms of heart failure, along...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07298044 · Bayer Phase 4 · 4 countries Recruiting
Recruiting Phase 4 Est. completion 15 July 2027
🇦🇹 AT🇧🇪 BE🇩🇪 DE🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 to 90 years old at the time of signing the consent form - People who have been diagnosed with ATTR-CM (a type of heart disease caused by abnormal protein deposits), confirmed by a specific scan (SPECT or SPECT/CT) or tissue biopsy done within the past 24 month...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07314268 · University of Sao Paulo General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇧🇷 BR

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with transthyretin cardiac amyloidosis (a condition where a protein called transthyretin builds up in the heart), with or without reduced heart function - People who are willing to follow the study's procedu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07322237 · Post Graduate Institute of Medical Education and Research, Chandigarh Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 January 2029
🇮🇳 IN

**Who might be able to join this trial:** - People who are between 18 and 65 years old - People who have been diagnosed with cirrhosis (scarring of the liver), confirmed by a tissue sample or by blood tests and an ultrasound scan - People whose heart scans show a specific type of heart function problem (where the heart...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07344480 · Deutsches Herzzentrum Muenchen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed through genetic testing with a RASopathy (a group of conditions caused by changes in a specific set of genes that affect how cells grow and communicate) - A heart scan (echocardiogram) has shown that the walls of your heart are thicker than normal, wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07351838 · Chinese Academy of Medical Sciences, Fuwai Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are 16 years old or older - A specific measurement of your heart's size (taken during a heart MRI scan) is within a certain range — below a set limit based on your sex (confirm with trial site for exact values) - Your heart's pumping ability is below 50%, and/or a heart M...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07358078 · Alnylam Pharmaceuticals Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 October 2030
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a heart condition caused by abnormal protein buildup, known as ATTR cardiomyopathy (ATTR-CM) - People who are starting treatment with a medication called vutrisiran, or another approved medication for ATTR-CM Who may not be able to join: - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07360067 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇰🇷 KR

Who might be able to join this trial: - People who are 19 years of age or older - People who have been diagnosed with sick sinus syndrome (a condition where the heart's natural pacemaker doesn't work properly) and are planned to receive their first permanent pacemaker or heart device implant - People, or their legal re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07361289 · Bristol-Myers Squibb Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 August 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older who have been diagnosed with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is abnormally thick and blocks blood flow out of the heart). - People who have already started taking a medication called mavacamten, or who are p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07367724 · China National Center for Cardiovascular Diseases Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes abnormally thick. - People who are 18 years of age or older at the time of the screening visit. - People whose heart is pumping at a normal or near-normal strength, a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07370688 · Erasmus Medical Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 July 2028
🇳🇱 NL

**Who might be able to join this trial:** - People aged 65 years or older - People who have severe aortic valve narrowing (a heart valve problem) combined with iron deficiency, and who have successfully undergone a TAVI procedure (a minimally invasive heart valve replacement) - People whose iron deficiency is confirmed...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07372196 · Meshalkin Research Institute of Pathology of Circulation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇷🇺 RU

Who might be able to join this trial: - You are a man or woman aged 18 years or older - You have a heart condition called HCM (hypertrophic cardiomyopathy) and have previously had a surgical procedure called a myectomy, after which you developed a specific type of abnormal heart electrical pattern (called LBBB) with a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07381894 · University of Manchester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇬🇧 GB

Who might be able to join this trial: - You have been diagnosed with a heart condition called Hypertrophic Cardiomyopathy (HCM), where the heart muscle becomes abnormally thick, and this diagnosis has been confirmed by a doctor through clinical assessment — not simply because of another condition like high blood pressu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07382128 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with a type of heart muscle disease called hypertrophic cardiomyopathy (a condition where the heart muscle becomes thickened), according to current European cardiology guidelines; OR a close blood relative (parent, child, or sibling) of someone...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07383025 · Bristol-Myers Squibb Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2029
🇯🇵 JP

Who might be able to join this trial: - You have a heart condition called obstructive hypertrophic cardiomyopathy (a thickening of the heart muscle that blocks blood flow) and your doctor has started you on a medication called Mavacamten for this condition at a medical facility in Japan during the study enrollment peri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07398950 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who have had at least one ECG (a heart rhythm test) and one echocardiogram (a heart ultrasound) recorded within the Yale New Haven Health System - People who have been diagnosed with a type of heart failure known as HFpEF or HFmrEF (heart failure where...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07420907 · Prolaio Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2030
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You are able to understand the study and agree to have your data collected - You are able to follow the study rules and schedule - You are able to understand and respond to instructions given in English - You have been diagnosed with a quali...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07426419 · Affinia Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 55 years old (male or female) - You have a specific type of genetic change (called a "truncating mutation") in a gene called BAG3 - You have a weakened, enlarged heart (called dilated cardiomyopathy) where your heart is pumping at less than 45% of its norma...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07443696 · Sinotau Pharmaceutical Group Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 85 years, of any gender - People who have been diagnosed with ischemic cardiomyopathy (a type of heart disease caused by reduced blood flow to the heart) - People who have significant blockages in the arteries that supply the heart - People whose heart's pumping...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07448623 · Novo Nordisk A/S Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 May 2027
🇳🇱 NL

Who might be able to join this trial: - People who have given written consent to participate before any study activities begin. - People of any gender. - People aged 60 years or older at the time of signing the consent form. - People who have a confirmed diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a co...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07479641 · Shandong Suncadia Medicine Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 55 years old (inclusive), of any gender - Your Body Mass Index (BMI) is between 19 and 28, your weight is between 50 kg and under 90 kg (if male), or between 45 kg and under 90 kg (if female) - A full physical examination and lab tests show no significa...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07483125 · Shanghai Zhongshan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with hypertrophic cardiomyopathy (a condition where the heart muscle becomes abnormally thick) through an ultrasound of the heart, whether or not there is a blockage affecting blood flow out of the heart - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07491718 · University of Edinburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 August 2028
🇬🇧 GB

Who might be able to join this trial: - You are male or female and over 18 years old - You have been diagnosed with a condition called takotsubo cardiomyopathy (sometimes called "broken heart syndrome") - You are able to understand and agree to take part by giving formal consent Who may not be able to join: - You are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07505199 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old. - You have been diagnosed with heart failure caused by reduced blood flow to the heart (ischemic cardiomyopathy), your heart is pumping at less than 35% of its normal capacity, and you have moderate to severe heart failure symptoms (such a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07516288 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who are aged 18 to 75 years old and have been diagnosed with dilated cardiomyopathy (a condition where the heart becomes enlarged and cannot pump blood properly) - People who previously received a single infusion of a specific immune-modifying cell therapy called iCDC, and...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07527715 · Shandong Provincial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇨🇳 CN

"Who might be able to join this trial: - Your heart's left main pumping chamber is larger than normal for your age and gender, and it is not pumping as strongly as it should be (confirm with trial site) Who may not be able to join: - You have significant blockages (more than 50%) in the major arteries that supply bloo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07541833 · Bristol-Myers Squibb Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇯🇵 JP

**Who might be able to join this trial:** - People who have signed a consent form approved by an ethics committee before any trial procedures begin (or whose legal representative has signed on their behalf) - People who have been diagnosed with obstructive hypertrophic cardiomyopathy (a condition where the heart muscl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07552142 · I.M. Sechenov First Moscow State Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇷🇺 RU

Who might be able to join this trial: - People who have been diagnosed with chronic heart failure, where the heart's pumping function is reduced, mildly reduced, or only slightly affected, and whose symptoms are moderate (able to do some daily activities but limited by breathlessness or fatigue). - People who were admi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07557498 · Bristol-Myers Squibb Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 December 2026
🇬🇧 GB

**Who might be able to join this trial:** - Adults aged 18 or older at the time the study begins looking at their records - People who have been formally diagnosed with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle becomes abnormally thick, blocking blood flow) - People who were prescribe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07563660 · Istanbul University - Cerrahpasa Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 August 2026
Turkey (Türkiye)

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with a specific heart muscle condition called arrhythmogenic right ventricular cardiomyopathy (ARVC), confirmed using recognised medical diagnostic guidelines - People who are currently being monitored and followed up...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07572032 · Kyungsub Song Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 20 May 2028
🇰🇷 KR

Who might be able to join this trial: - You must be 18 years of age or older. - Before your heart procedure, a heart scan (echocardiogram) showed that your heart's pumping strength was 40% or below. - You have successfully had surgery or a procedure to fix a treatable heart problem, such as heart valve surgery (mitral,...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07574697 · Barts & The London NHS Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇬🇧 GB

Who might be able to join this trial: - Adults aged 18 or older who had ongoing (persistent) atrial fibrillation (an irregular heart rhythm) before undergoing a heart procedure to correct the rhythm (either catheter ablation or cardioversion) - **Group 1 (Cases):** People whose heart pumping function was weakened (mea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07595354 · Alder Hey Children's NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇬🇧 GB

Who might be able to join this trial: - You are being checked for a heart condition called HCM (hypertrophic cardiomyopathy) because a family member has it or because of a genetic test result - You are between 10 and 18 years old (including those ages) - You are already a patient at the inherited cardiac conditions cli...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07600177 · Oregon Health and Science University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thickened and blocks blood flow) with a documented blockage measurement of 50 mmHg or more, and who are currently taking the medication mavacamten through a standard...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07604467 · University Medical Centre Ljubljana Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇸🇮 SI

Who might be able to join this trial: - You must be 18 years old or older - You have been diagnosed with Takotsubo Syndrome (a type of stress-related heart condition) based on recognised international diagnostic standards - You have agreed to take part and signed a consent form Who may not be able to join: - You are u...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07606274 · Nuevocor Pte. Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2030
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older and are able to give their own consent to participate - People who have been clinically diagnosed with a type of heart muscle disease called dilated cardiomyopathy (DCM) caused by a change in the LMNA gene, where the left side of the h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07617844 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - People aged 18 years or older, of any gender. - People who have a suspected or confirmed heart condition (such as blocked arteries in the heart, heart muscle disease, heart inflammation, or heart valve problems) where a cardiac MRI scan is needed to understand the cause or assess...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07633587 · Groupe Hospitalier Pitie-Salpetriere Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇫🇷 FR

Who might be able to join this trial: - You are a cancer patient who has received at least one immunotherapy drug known as an immune checkpoint inhibitor - You have been recorded in an international registry as possibly, probably, or definitely having developed heart inflammation (myocarditis) linked to your immune che...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07658222 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have cirrhosis (severe liver scarring) that has caused serious complications, such as internal bleeding related to liver pressure, episodes of confusion caused by liver disease, or fluid build-up in the abdomen - People whose liver disease is rated as moderately s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07689331 · Semmelweis University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇭🇺 HU

Who might be able to join this trial: - People who have been diagnosed with systemic amyloidosis (a disease where abnormal proteins build up in organs and tissues) - People who are 18 years of age or older at the time of joining the trial - People whose treating doctor has given consent for their participation - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07692256 · Ain Shams University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇪🇬 EG

Who might be able to join this trial: - Children and young people aged 1 month to 18 years old. - People who have been diagnosed with heart failure, confirmed by heart ultrasound showing the heart is not pumping or filling properly, along with signs of fluid build-up or poor blood flow. - People whose heart failure is...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Cardiomyopathy. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Cardiomyopathy Australia New Zealand (CMANZ) is the dedicated body for people living with cardiomyopathy on both sides of the Tasman.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.